Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-03-13	6.316 $	+5.27%	22,144
26-03-12	6.000 $	-0.17%	67,463
26-03-11	6.010 $	-0.99%	42,871
26-03-10	6.070 $	+2.53%	50,416
26-03-09	5.920 $	+1.37%	18,894

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.000USD

Average target price

16.00USD

Spread / Average Target

+166.67%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 12:51:00 2026-03-13 EDT			5-day change	1st Jan Change
6.215 ^USD	+3.58%		+8.15%	-8.46%

03-10	ImageneBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-17	ImageneBio, Inc. Announces Resignation of Steven Hui Wang as Member of the Board of Directors, Effective on February 12, 2026	CI

Capitalization	67.09M 58.2M 52.62M 50.25M 91.39M 6.19B 94.59M 626M 249M 2.96B 252M 246M 10.68B	P/E ratio 2026 *	-3.18x	P/E ratio 2027 *	-2.46x
Enterprise value	67.09M 58.2M 52.62M 50.25M 91.39M 6.19B 94.59M 626M 249M 2.96B 252M 246M 10.68B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	89.5%	Yield 2026 *	-	Yield 2027 *	-

03-10	ImageneBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-17	ImageneBio, Inc. Announces Resignation of Steven Hui Wang as Member of the Board of Directors, Effective on February 12, 2026	CI
02-10	ImageneBio, Inc. Appoints Ben Porter-Brown as Chief Medical Officer, Effective February 16, 2026	CI
12-18	ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025	CI
11-25	Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target	MT
11-12	ImageneBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	ImageneBio, Inc. Appoints Joseph P. Slattery to the Board, Effective November 1, 2025, and as Chair of the Audit Committee of the Board, Effective November 18, 2025	CI
25-10-29	Miragene Inc. Announces Extension of Key Service Agreement	CI
25-10-29	Imagenebio Inc elects not to renew agreement with Miragene - SEC filing	RE
25-10-24	Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target	MT
25-10-22	ImageneBio, Inc. Appoints Kristin Yarema as Interim Principal Financial Officer, Effective October 21, 2025	CI
25-10-10	ImageneBio, Inc. Announces Resignation of Jotin Marango as Principal Financial Officer, Effective October 20, 2025	CI
25-10-10	ImageneBio, Inc. Announces Resignation of Jotin Marango as Chief Financial Officer, Effective October 20, 2025	CI

11-25	Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target	MT
25-10-24	Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target	MT
25-07-25	Wedbush Cuts Price Target on Ikena Oncology to $23 From $25, Keeps Neutral Rating	MT
24-05-29	HC Wainwright Adjusts Price Target on Ikena Oncology to $4 From $11, Maintains Buy Rating	MT
24-05-29	Wedbush Downgrades Ikena Oncology to Neutral From Outperform After Discontinuation of Lead Program IK-930, Adjusts PT to $2 From $8	MT

ImageneBio, Inc. Stock

Equities

IMA

US45175G2075

Biotechnology & Medical Research

Valuation: ImageneBio, Inc.

Chart: ImageneBio, Inc.

Latest news: ImageneBio, Inc.

Analysts' recommendations: ImageneBio, Inc.

Press Releases: ImageneBio, Inc.

Quotes and Performance

Course Extremes

ETFs: ImageneBio, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-10	ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update	GL
03-10	ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update	AQ
02-26	ImageneBio to Participate in Leerink Global Healthcare Conference	GL
02-10	ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer	GL
02-10	ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer	AQ

1 day	+3.58%
1 week	+8.15%
Current month	-6.01%
1 month	-8.60%
3 months	+2.37%
6 months	-29.51%
Current year	-8.46%

1 week	5.82	6.5
1 month	5.82	7.25
Current year	5.82	7.6
1 year	5.7	18
3 years	5.7	18
5 years	5.7	18
10 years	5.7	18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IMAGENEBIO, INC.	+3.58%	+8.15%	-	-	67.09M
LONZA GROUP AG	-0.72%	-4.60%	-11.02%	-8.56%	43.38B
BEONE MEDICINES AG	-0.25%	-6.00%	+11.18%	+27.36%	31.64B
CELLTRION, INC.	-0.24%	-2.84%	+14.35%	+45.06%	30.26B
IQVIA HOLDINGS INC.	+1.61%	-5.07%	-8.70%	-16.39%	27.35B
REVOLUTION MEDICINES, INC.	+0.96%	-2.54%	+145.71%	+324.71%	18.84B
ASCENDIS PHARMA A/S	-1.64%	-6.51%	+47.72%	+109.00%	14.06B
MEDPACE HOLDINGS, INC.	+1.63%	-4.02%	+42.07%	+159.12%	12.6B
EUROFINS SCIENTIFIC SE	-0.29%	-4.80%	+21.98%	-2.54%	12.52B
IONIS PHARMACEUTICALS, INC.	-1.35%	-3.97%	+116.11%	+111.73%	11.95B
Average	+0.27%	-4.05%	+42.16%	+83.28%	20.27B
Weighted average by Cap.	-0.10%	-4.33%	+28.04%	+61.05%

	2026 *	2027 *
Net sales	-	-
Net income	-44.86M -38.92M -35.19M -33.6M -61.12M -4.14B -63.26M -419M -166M -1.98B -168M -165M -7.14B	-61.49M -53.35M -48.23M -46.05M -83.77M -5.68B -86.7M -574M -228M -2.71B -231M -226M -9.79B
Net Debt	-	-